人人干人人摸人人骑-人人干人人澡-人人干天天搞夜夜爽-人人干综合-人人搞人人摸-人人搞人人模

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 国产第一影院在线观看 | 国产美女在线观看 | 无码AV 丰满AV 床震AV | 亚洲AV乱码一区二区三区人人爱 | 亚洲综合福利电影 | 波多野结衣成人在线 | 夜色国产精 | 免费三级网 | 成全视频在线观看大全 | 国产a观看免费完整版 | 欧美特级一级 | 国产刺激真实乱对白 | 亚洲欧美日韩综合久久 | 国产爆乳无码一 | 91桃色污视频。 | 国产精品拍自在线观看 | 亚洲中文字幕精品一 | H精品动漫导航 | 中文字幕爱你懂你你 | 超碰人人操人人看 | 懂色av一区二区三区蜜桃 | 免费午夜 | 久久88台湾三级香港三级 | 91精品久久人人妻人人做 | 国产精品2025不卡在线观看 | 国产白嫩极品 | 国产精品一区二区手机在线观看 | 99热99r| 无码一区二区三区老色鬼 | 制服丝袜麻麻在 | 韩国三级日本三级美三级 | 国产河南妇女 | 国产中年夫妇高潮精品视频 | 久久精品蜜桃AV无码字幕张津瑜 | 日本中文视频 | 不卡二区 | 亚洲欧美字幕一区 | 91精品久久久久久综合五月天 | 涩涩视频 | 免费追剧免费观看在线 | 最新日韩中文字幕国产 |